Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT01436175




Registration number
NCT01436175
Ethics application status
Date submitted
15/09/2011
Date registered
19/09/2011
Date last updated
14/06/2021

Titles & IDs
Public title
SPD489 Adult Major Depressive Disorder (MDD) Open-label Safety and Tolerability Rollover Extension Study
Scientific title
A Phase 3, Open-label, Multicenter, 12-month Extension Safety and Tolerability Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder With Residual Symptoms or Inadequate Response Following Treatment With an Antidepressant
Secondary ID [1] 0 0
2011-003019-47
Secondary ID [2] 0 0
SPD489-329
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Major Depressive Disorder 0 0
Condition category
Condition code
Mental Health 0 0 0 0
Depression

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - SPD489 (Lisdexamfetamine dimesylate) + Antidepressant

Experimental: SPD489 + Antidepressant -


Treatment: Drugs: SPD489 (Lisdexamfetamine dimesylate) + Antidepressant
SPD489 20mg, 30mg, 50mg, or 70mg + Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release or duloxetine hydrochloride) oral, once daily for 52 weeks
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Columbia-Suicide Severity Rating Scale (C-SSRS)
Timepoint [1] 0 0
Week 5 up to Week 52/Early Termination(ET)
Primary outcome [2] 0 0
Change From Baseline in Systolic Blood Pressure at Week 52
Timepoint [2] 0 0
Baseline, Week 52/ET
Primary outcome [3] 0 0
Change From Baseline in Diastolic Blood Pressure at Week 52
Timepoint [3] 0 0
Baseline, Week 52/ET
Primary outcome [4] 0 0
Change From Baseline in Pulse Rate at Week 52
Timepoint [4] 0 0
Baseline, Week 52/ET
Secondary outcome [1] 0 0
Change From Baseline in Sheehan Disability Scale (SDS) Total Score at Week 52/ET
Timepoint [1] 0 0
Baseline, Week 52/ET
Secondary outcome [2] 0 0
Number of Participants With Improvement on Clinical Global Impressions - Global Improvement (CGI-I)
Timepoint [2] 0 0
Week 52/ET
Secondary outcome [3] 0 0
Short Form-12 Health Survey Version 2 (SF-12V2)
Timepoint [3] 0 0
Week 52/ET
Secondary outcome [4] 0 0
EuroQoL Group 5-Dimension 5-Level Self Report Questionnaire (EQ-5D-5L): Mobility
Timepoint [4] 0 0
Week 52/ET
Secondary outcome [5] 0 0
EuroQoL Group 5-Dimension 5-Level Self Report Questionnaire (EQ-5D-5L): Self-Care
Timepoint [5] 0 0
Week 52/ET
Secondary outcome [6] 0 0
EuroQoL Group 5-Dimension 5-Level Self Report Questionnaire (EQ-5D-5L): Usual Activities
Timepoint [6] 0 0
Week 52/ET
Secondary outcome [7] 0 0
EuroQoL Group 5-Dimension 5-Level Self Report Questionnaire (EQ-5D-5L): Pain/Discomfort
Timepoint [7] 0 0
Week 52/ET
Secondary outcome [8] 0 0
EuroQoL Group 5-Dimension 5-Level Self Report Questionnaire (EQ-5D-5L): Anxiety/Depression
Timepoint [8] 0 0
Week 52/ET
Secondary outcome [9] 0 0
EuroQoL Group 5-Dimension 5-Level Self Report Questionnaire (EQ-5D-5L): Visual Analog Scale
Timepoint [9] 0 0
Week 52/ET
Secondary outcome [10] 0 0
Quick Inventory of Depressive Symptomatology - Self Report (QIDS-SR)
Timepoint [10] 0 0
Week 52/ET
Secondary outcome [11] 0 0
Quality of Life Enjoyment Satisfaction Questionnaire Short Form (Q-LES-Q-SF)
Timepoint [11] 0 0
Week 52/ET
Secondary outcome [12] 0 0
Change From Baseline in Sexual Functioning Questionnaire - 14 Item Scale (CSFQ-14) Total Score at Week 52/ET
Timepoint [12] 0 0
Baseline, Week 52/ET
Secondary outcome [13] 0 0
Amphetamine Cessation Symptom Assessment (ACSA) Total Score
Timepoint [13] 0 0
Week 53
Secondary outcome [14] 0 0
Patient Resource Utilization Questionnaire - Major Depressive Disorder (PRUQ-MDD)
Timepoint [14] 0 0
Week 52/ET
Secondary outcome [15] 0 0
PRUQ-MDD - Number of Days of Resource Utilization
Timepoint [15] 0 0
Week 52/ET
Secondary outcome [16] 0 0
PRUQ-MDD - Number of Events (Visit to Health Care Provider/Visit to Hospital Facilities/Number of Times a Test Was Performed)
Timepoint [16] 0 0
Week 52/ET
Secondary outcome [17] 0 0
PRUQ-MDD - Number of Hours
Timepoint [17] 0 0
Week 52/ET
Secondary outcome [18] 0 0
PRUQ-MDD - Effect of Depressive Symptoms
Timepoint [18] 0 0
Week 52/ET

Eligibility
Key inclusion criteria
* Subject has completed 1 of the respective short-term antecedent SPD489 MDD studies and did not experience any clinically significant AEs in the antecedent study that would preclude exposure to SPD489.
Minimum age
18 Years
Maximum age
65 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Subject has any current co-morbid Axis I or Axis II psychiatric disorder (including a lifetime history of psychosis) which was not present or recognized at entry into the antecedent study or has a concurrent chronic or acute illness or unstable medical condition that may deteriorate that could confound the results of safety assessments, increase risk to the subject or lead to difficulty complying with the protocol

Study design
Purpose of the study
Treatment
Allocation to intervention
Not applicable
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Stopped early
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
27/02/2012
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
27/03/2014
Sample size
Target
Accrual to date
Final
1570
Recruitment in Australia
Recruitment state(s)
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
Arkansas
Country [4] 0 0
United States of America
State/province [4] 0 0
California
Country [5] 0 0
United States of America
State/province [5] 0 0
Colorado
Country [6] 0 0
United States of America
State/province [6] 0 0
Connecticut
Country [7] 0 0
United States of America
State/province [7] 0 0
Florida
Country [8] 0 0
United States of America
State/province [8] 0 0
Georgia
Country [9] 0 0
United States of America
State/province [9] 0 0
Illinois
Country [10] 0 0
United States of America
State/province [10] 0 0
Indiana
Country [11] 0 0
United States of America
State/province [11] 0 0
Kansas
Country [12] 0 0
United States of America
State/province [12] 0 0
Kentucky
Country [13] 0 0
United States of America
State/province [13] 0 0
Louisiana
Country [14] 0 0
United States of America
State/province [14] 0 0
Maryland
Country [15] 0 0
United States of America
State/province [15] 0 0
Massachusetts
Country [16] 0 0
United States of America
State/province [16] 0 0
Missouri
Country [17] 0 0
United States of America
State/province [17] 0 0
Nebraska
Country [18] 0 0
United States of America
State/province [18] 0 0
Nevada
Country [19] 0 0
United States of America
State/province [19] 0 0
New Jersey
Country [20] 0 0
United States of America
State/province [20] 0 0
New Mexico
Country [21] 0 0
United States of America
State/province [21] 0 0
New York
Country [22] 0 0
United States of America
State/province [22] 0 0
North Carolina
Country [23] 0 0
United States of America
State/province [23] 0 0
Ohio
Country [24] 0 0
United States of America
State/province [24] 0 0
Oklahoma
Country [25] 0 0
United States of America
State/province [25] 0 0
Oregon
Country [26] 0 0
United States of America
State/province [26] 0 0
Pennsylvania
Country [27] 0 0
United States of America
State/province [27] 0 0
Rhode Island
Country [28] 0 0
United States of America
State/province [28] 0 0
South Carolina
Country [29] 0 0
United States of America
State/province [29] 0 0
Tennessee
Country [30] 0 0
United States of America
State/province [30] 0 0
Texas
Country [31] 0 0
United States of America
State/province [31] 0 0
Utah
Country [32] 0 0
United States of America
State/province [32] 0 0
Virginia
Country [33] 0 0
United States of America
State/province [33] 0 0
Washington
Country [34] 0 0
United States of America
State/province [34] 0 0
Wisconsin
Country [35] 0 0
Canada
State/province [35] 0 0
British Columbia
Country [36] 0 0
Canada
State/province [36] 0 0
Ontario
Country [37] 0 0
Canada
State/province [37] 0 0
Quebec
Country [38] 0 0
Chile
State/province [38] 0 0
Santiagio
Country [39] 0 0
Chile
State/province [39] 0 0
Santiago
Country [40] 0 0
Chile
State/province [40] 0 0
Santiego
Country [41] 0 0
Chile
State/province [41] 0 0
Antofagasta
Country [42] 0 0
Czechia
State/province [42] 0 0
Praha Vychod
Country [43] 0 0
Czechia
State/province [43] 0 0
Brno
Country [44] 0 0
Czechia
State/province [44] 0 0
Horovice
Country [45] 0 0
Czechia
State/province [45] 0 0
Kutna Hora
Country [46] 0 0
Czechia
State/province [46] 0 0
Litomerice
Country [47] 0 0
Czechia
State/province [47] 0 0
Prague 10
Country [48] 0 0
Czechia
State/province [48] 0 0
Prague
Country [49] 0 0
Estonia
State/province [49] 0 0
Tallinn
Country [50] 0 0
Estonia
State/province [50] 0 0
Tartu
Country [51] 0 0
Finland
State/province [51] 0 0
Helsinki
Country [52] 0 0
Finland
State/province [52] 0 0
Kuopio
Country [53] 0 0
Finland
State/province [53] 0 0
Turku
Country [54] 0 0
Germany
State/province [54] 0 0
Berlin
Country [55] 0 0
Germany
State/province [55] 0 0
Bochum
Country [56] 0 0
Germany
State/province [56] 0 0
Leipzig
Country [57] 0 0
Germany
State/province [57] 0 0
Munchen
Country [58] 0 0
Germany
State/province [58] 0 0
Nuernberg
Country [59] 0 0
Germany
State/province [59] 0 0
Schwerin
Country [60] 0 0
Germany
State/province [60] 0 0
Westerstede
Country [61] 0 0
Germany
State/province [61] 0 0
Wuerzburg
Country [62] 0 0
Hungary
State/province [62] 0 0
Budapest
Country [63] 0 0
Hungary
State/province [63] 0 0
Debrecen
Country [64] 0 0
Mexico
State/province [64] 0 0
Mazatian
Country [65] 0 0
Mexico
State/province [65] 0 0
Monterrey
Country [66] 0 0
Poland
State/province [66] 0 0
Bialystok
Country [67] 0 0
Poland
State/province [67] 0 0
Chelmno
Country [68] 0 0
Poland
State/province [68] 0 0
Gdansk
Country [69] 0 0
Poland
State/province [69] 0 0
Gorlice
Country [70] 0 0
Poland
State/province [70] 0 0
Kielce
Country [71] 0 0
Poland
State/province [71] 0 0
Zuromin
Country [72] 0 0
Puerto Rico
State/province [72] 0 0
San Juan
Country [73] 0 0
Romania
State/province [73] 0 0
Bucuresti
Country [74] 0 0
Romania
State/province [74] 0 0
Targoviste
Country [75] 0 0
Romania
State/province [75] 0 0
Targu Mures
Country [76] 0 0
South Africa
State/province [76] 0 0
Cape Town
Country [77] 0 0
South Africa
State/province [77] 0 0
Western Cape
Country [78] 0 0
Spain
State/province [78] 0 0
Barcelona
Country [79] 0 0
Spain
State/province [79] 0 0
Madrid
Country [80] 0 0
Spain
State/province [80] 0 0
Oviedo
Country [81] 0 0
Spain
State/province [81] 0 0
Salamanca
Country [82] 0 0
Spain
State/province [82] 0 0
Zamora
Country [83] 0 0
Spain
State/province [83] 0 0
Zaragoza

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Shire
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This study is an optional continuation of previous short-term adult major depressive disorder (MDD) augmentation studies. Patients may only take part in this long-term, open-label research study if they completed a previous double-blind MDD augmentation study using SPD489.
Trial website
https://clinicaltrials.gov/study/NCT01436175
Trial related presentations / publications
Public notes
This record is viewable in the ANZCTR as it had previously listed Australia and/or New Zealand as a recruitment site, however these sites have since been removed

Contacts
Principal investigator
Name 0 0
Study Director
Address 0 0
Takeda
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT01436175